SCHEMBL2291165

SCHEMBL2291165

Cc1cccc(C)c1Nc1cn2c(F)cccc2n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.41
▸ TP53 P04637 4/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ GAA P10253 8/20 0.40
▸ HTT P42858 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ P2RX7 Q99572 1/20 0.37
▸ SRC P12931 2/20 0.36
▸ HTR1D P28221 1/20 0.36
▸ RAB9A P51151 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292832 0.75 LCK (0.42) MAPTSMN1; SMN2GAAKMT2ARAB9A
SCHEMBL2295454 0.75 MAP3K5 (0.45) MAPTTP53SMN1; SMN2GAAP2RX7
SCHEMBL2289469 0.74 MAPT (0.44) MAPTTP53SMN1; SMN2GAAHTT
SCHEMBL15004601 0.73 RAB9A (0.38) MAPTSMN1; SMN2GAAHTTNPSR1
SCHEMBL5547638 0.66 KDM4E (0.33) GAARAB9AALDH1A1HPGD
SCHEMBL2285933 0.66 NPC1 (0.45) MAPTTP53SMN1; SMN2GAAMAPK1
SCHEMBL13050204 0.66 RAB9A (0.33) GAAKMT2ARAB9AALDH1A1HPGD
SCHEMBL2291938 0.64 MAPT (0.38) MAPTTP53SMN1; SMN2GAAHTT
SCHEMBL6748393 0.64 RAB9A (0.34) RAB9A
SCHEMBL2927525 0.63 ALDH1A1 (0.54) MAPTNPSR1L3MBTL1HTR1DRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 — — US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 MAPT 1138/4885TP53 4410/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback